Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-naïve Patients.
Options
BORIS DOI
Date of Publication
October 20, 2020
Publication Type
Article
Division/Institute
Contributor
Hömke, Rico | |
Sander, Peter | |
Avihingsanon, Anchalee | |
Collantes, Jimena | |
Loiseau, Chloé | |
Borrell, Sonia | |
Reinhard, Miriam | |
Wilkinson, Robert J | |
Yotebieng, Marcel | |
Böttger, Erik C | |
Gagneux, Sebastien |
Series
Antimicrobial agents and chemotherapy
ISSN or ISBN (if monograph)
0066-4804
Publisher
American Society for Microbiology
Language
English
Publisher DOI
PubMed ID
32868333
Description
Mutations in the genes of the F420 signaling pathway, including dnn, fgd1, fbiA, fbiB, fbiC, and fbiD, of Mycobacterium tuberculosis (Mtb) complex can lead to delamanid resistance. We searched for such mutations among 129 Mtb strains from Asia, South-America, and Africa using whole-genome sequencing; 70 (54%) strains had at least one mutation in one of the genes. For ten strains with mutations, we determined the minimum inhibitory concentration (MIC) of delamanid. We found one strain from a delamanid-naïve patient carrying the natural polymorphism Tyr29del (ddn) that was associated with a critical MIC to delamanid.
File(s)
| File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
|---|---|---|---|---|---|---|---|
| Reichmuth_AntimicrobAgentsChemother_2020.pdf | text | Adobe PDF | 270.45 KB | Attribution (CC BY 4.0) | published |